SecBot SecBot
SECBOTREPLAY Home › Report › PRAX

PRAX · Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a…

Praxis Precision Medicines, Inc. · PRESS-RELEASE filed May 7, 2026 at 08:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed May 7, 2026 at 08:00 ET

Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68, but the headline is the FDA acceptance of NDAs for ulixacaltamide (PDUFA Jan 29, 2027) and relutrigine (priority review, PDUFA Sep 27, 2026), positioning for two U.S. launches within eight months. The company also reported a 77% placebo-adjusted seizure reduction for elsunersen in early-seizure-onset SCN2A-DEE and maintains a $1.4B cash runway into 2028, funding multiple upcoming catalysts including POWER1 (FOS) topline in Q2 2026 and EMERALD (broad DEEs) in Q4 2026.

  • FDA accepted NDA for ulixacaltamide in Essential Tremor with PDUFA Jan 29, 2027
  • FDA accepted relutrigine NDA with priority review for SCN2A/SCN8A DEEs, PDUFA Sep 27, 2026
  • Elsunersen showed 77% placebo-adjusted seizure reduction in EMBRAVE Part A (p=0.015)
  • Cash and investments $1.4B as of March 31, 2026, up from $926.1M at Dec 31, 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access